Merck & Co., Inc. (NYSE:MRK) announced Monday that it has entered into a multi-year collaboration agreement with NGM Biopharmaceuticals Inc., a privately held biotechnology company, to research, develop, as well as commercialize innovative biologic therapies ranging across a wide array of therapeutics.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for developing countries.
Merck & Co., Inc. (NYSE:MRK) ended up paying $8.4 billion to acquire Cubist Pharmaceuticals Inc (NASDAQ:CBST), a 37% premium over Cubist’s closing stock price of $74.36 Friday; however, by Monday morning, this amount looked at least $2 billion too high as Cubist lost a key patent-infringement case pertaining to its blockbuster drug, Cubicin.
Editor’s Note: The following post comes to us from Klaus J. Hopt, a professor and director (emeritus) at the Max-Planck-Institute for Comparative and International Private Law, in Hamburg and was advisor inter alia for the European Commission, the German legislator and the Ministries of Finance and of Justice.
Banks are special, so is corporate governance of banks.
Editor's Note: The following post comes to us from Lawrence A. Cunningham, Henry St. George Tucker III Research Professor of Law at George Washington University Law School.
“Prosecutors in the boardroom” is a slogan reflecting an unintended early 21st century overlap of corporate governance and corporate criminal liability.
By CFA Institute Contributors:
Matt, Orsagh, CFA, CIPM
From the development of a corporate governance scorecard in Southeast Asia and executive and board transparency in Brazil to debate over redrafting the corporate governance code in the France, it’s time to span the corporate governance globe to review important developments from the month of June.
Grant Sawiak is a partner at Fogler Rubinoff and a former staffer at the TSX who recently successfully advised a group of dissidents at Continental Precious Minerals Inc., a small mining company with an operation in Sweden.
Sawiak’s involvement in Continental’s proxy battle – which now has a new team of directors that doesn’t include the chief executive – gave him a first-hand look at corporate governance in the junior mining sector, a sector that’s home to thousands of companies which, in market cap terms, is typical of much of corporate Canada.
Chemistfrog submits:Ariad Pharmaceuticals (NASDAQ: ARIA) captured Merck’s (NYSE: MRK) attention enough with its cancer drug, ridaforolimus, in July 2007 to forge a partnership to help Ariad through several clinical trials for multiple cancer indications.